Soluble proteins and haptens on bone marrow-derived dendritic cells are presented to host CD4 T cells in an MHC-restricted manner

International Immunology

Volumn 14, Issue 5, 2002, Pages 493-502

  Olasz, Edit B ^a   Linton, Jay ^a   Katz, Stephen I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigen presentation; Contact sensitivity; Cross presentation; Delayed type hypersensitivity; Dendritic cell; MHC

Indexed keywords

CD4 ANTIGEN; CYTOCHROME C; HAPTEN; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CELL CULTURE; CELL STIMULATION; CHICKEN; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; EGG; FEMALE; HELPER CELL; HOST CELL; HYBRIDOMA; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PIGEON; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIZATION;

EID: 0036094973     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/14.5.493     Document Type: Article

References (42)

1. The dendritic cell system and its role in immunogenicity
2. Dendritic cells and the control of immunity
3. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
4. Induction of antitumor immunity using bone marrow-generated dendritic cells
5. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
6. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients
7. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
8. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
9. Dendritic cell based therapy of cancer
10. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
11. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
12. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
13. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
14. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
15. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
16. Ia antigens in mouse skin are predominantly expressed on Langerhans cells
17. Contact hypersensitivity in MHC class II-deficient mice depends on CD8 T lymphocytes primed by immunostimulating Langerhans cells
18. Dose-dependent T cell tolerance to an immunodominant self peptide
19. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells
20. + epidermal cells
21. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation
22. -dendritic cells induce hapten-specific immune responses in vitro and in vivo
23. Cross-presentation, dendritic cells, tolerance and immunity
24. Constitutive class I-restricted exogenous presentation of self antigens in vivo
25. + T cells
26. Peripheral tolerance of CD4 T cells following local activation in adolescent mice
27. + helper T cells and self antigen-presenting cells in the mouse
28. Mechanism of liver allograft rejection: The indirect recognition pathway
29. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection
30. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides
31. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
32. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo
33. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
34. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells
35. Dendritic cells acquire antigens from live cells for cross-presentation to CTL
36. A novel MHC class II epitope expressed in thymic medulla but not cortex
37. Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ
38. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node
39. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction
40. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose
41. - dendritic cells cross-prime cytotoxic T cells in vivo
42. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo